Inivata is a Leader in Liquid Biopsy

Unlocking essential genomic information from a simple
blood draw to transform the care of cancer patients

Inivata is a Leader in Liquid Biopsy

Unlocking essential genomic information from a simple
blood draw to transform the care of cancer patients

Liquid Biopsy Unlocking essential genomic information from a simple blood draw to transform the care of cancer patients

InVision® platform

Our InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients

InVisionFirst®Lung Our US Medicare-reimbursed lead product InVisionFirst®Lung is already transforming the lives of advanced NSCLC patients

InVisionFirst®Lung

Our US Medicare-reimbursed lead product InVisionFirst®Lung is already transforming the lives of advanced NSCLC patients

Radar™  A multi-tumor assay for the detection of residual disease and recurrence based on the InVision® liquid biopsy platform

Radar

A multi-tumor assay for the detection of residual disease and recurrence based on the InVision® liquid biopsy platform

Our Mission

We are transforming the lives of cancer patients and their families through the power of liquid biopsy

InvisionFirst Lung - ctDNA Liquid Biopsy Test

Our Technology - Liquid Biopsy Testing

Our Technology

Contact Us at Inivata

Contact Us

Latest News and Events

Inivata and Collaborators to Present New Data to Support the Application of RaDaR™ MRD Assay Across Tumor Types at ESMO Congress 2022

Inivata, a leader in liquid biopsy, alongside collaborators, will present new data on its RaDaR™ assay for the detection of minimal residual disease (MRD) and recurrence at the European Society for Medical Oncology (ESMO) Congress, taking place on 9-13 September 2022. Inivata and NeoGenomics, Inivata’s parent company, will host a joint booth in the exhibition hall at the conference. Read More

Liquid biopsy for detection of molecular residual disease and recurrence in head and neck squamous cell carcinoma

Susanne Flach, Karen Howarth, Sophie Hackinger, Christodoulos Pipinikas, Pete Ellis, Kirsten McLay, Giovanni Marsico, Patricia Rojas, ... Read More

SABCS 2022

SABCS 2022

Event expiration date display - 6 - 10 DEC 2022

Location: San Antonio, Texas Read More

Changing Lives

Patients are at the heart of everything we do.

Our first product is for advanced Non-Small Cell lung Cancer and our world-leading tests are already impacting patients’ lives. 

This is the story of the first patient Inivata tested.

Transforming the lives of Cancer Patients and Their Families

As a dynamic and innovative company, we focus on the development of ground-breaking technology in a fast-paced and international setting.

Our team of talented and driven individuals work together to combine their energy and expertise in world-class research, product development and commercialization. Join us.

ICYMI #TeamInivata and collaborators presented ‘Updated follow-up data and biomarker analysis of pre-operative ipilimumab and nivolumab in locoregional advanced urothelial cancer (NABUCCO)’ at #ESMO22. View here: https://www.inivata.com/wp-content/uploads/2022/09/Stockem-et-al._NABUCCO-ESMO-2022-FINAL.pdf @myESMO #MRD #data

Come and meet #TeamInivata at this year’s 12th Annual World Clinical Biomarkers & #CDx Summit, taking place from 26-29 September.

Find out more here: https://world-cdx.com/

#drugdevelopment #diagnostics #oncology

ICYMI #TeamInivata and collaborators presented a poster on ‘Liquid biopsy for detection of molecular residual disease and recurrence in head and neck squamous cell carcinoma’ at #ESMO22. View here: https://www.inivata.com/wp-content/uploads/2022/09/LIONESS_ESMO2022_FINAL.pdf
@myESMO #data #presentation

LinkedIn tracking code Twitter tracking code